Centre médical Chilpéric - 56 boulevard Chilpéric ■ 77500 Chelles - Standard 01.83.62.95.47 - cmc56chelles@gmail.com




Centre médical Chilpéric

Le centre Chilpéric est un centre de consultation médico-chirurgical pluridisciplinaire au centre ville de CHELLES (77).


cancer de prostate résistant à la castration (english)
  par Dr Philippe PEDRON
World J Urol. 2012 Apr 15. [Epub ahead of print]

A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA.

Masson-Lecomte A, Guy L, Pedron P, Bruyere F, Rouprêt M, Nsabimbona B, Dahan M, Hoffman P, Salomon L, Vordos D, Hoznek A, Le Corvoisier P, Morel P, Abbou C, de la Taille A.

Source

INSERM U955EQ07 - Department of Urology, CHU Henri Mondor, 51 av du Maréchal de Lattre de Tassigny, 94000, Créteil, France.

Abstract

PURPOSE:

At the time of castration resistance, it is recommended to realize hormonal manipulations before chemotherapy. We evaluated the impact of a switch from GnRH agonist to antagonist in patients with castration-resistant prostate cancer on PSA and testosterone levels at 3 months.

METHODS:

Retrospectively, 17 patients from 5 different centers undergoing androgen deprivation therapy and presenting rising PSA confirmed on 3 blood samples 2 weeks apart and despite a castrate testosterone level (<0.5 ng/ml) were reviewed. Antiandrogen withdrawal syndrome had been tested before the switch. Degarelix was administered as followed: 240 mg for the first injection and then 80 mg every month, subcutaneously. We evaluated the PSA and testosterone level variation 3 months after the switch. Patients who experienced a variation in PSA of less than 10% compared to the baseline or who had a more than 10% PSA decrease were defined as responders.

RESULTS:

Mean PSA level at the switch was 34.3 ± 50.3 ng/ml, with a mean testosterone level of 0.21 ± 0.13 ng/ml. Three months after the switch, mean PSA level was 59.9 ± 81.6 ng/ml (P = 0.061), with a mean testosterone level of 0.19 ± 0.08 ng/ml (P = 0.086). At 3 months, 4 patients (23%) responded to therapy. Thirteen patients (77%) experienced a rise in PSA of more than 10% compared to baseline; 41% of patients decreased their testosterone level. The limitations of this study are its retrospective nature and the limited number of patients.

CONCLUSION:

Switch from an agonist to an antagonist of GnRH has a limited impact on PSA at 3 months in castration-resistant prostate cancer patients.

 




Publié le 26/04/2012


© Tous droits réservés 2015